Trial reportDiabetes technology & therapeutics2015
Hypoglycemia Reduction and Changes in Hemoglobin A1c in the ASPIRE In-Home Study.
Trial report in Diabetes technology & therapeutics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 58 citations in OpenAlex.
- Pooled it
- Improved Glycemia with Hybrid Closed-Loop Versus Continuous Subcutaneous Insulin Infusion Therapy: Results from a Randomized Controlled Trial.Diabetes technology & therapeutics · 2023Trial
- Timing of CGM initiation in pediatric diabetes: The CGM TIME Trial.Pediatric diabetes · 2021Trial
- Dose-dependent glycometabolic effects of sotagliflozin on type 1 diabetes over 12 weeks: The inTandem4 trial.Diabetes, obesity & metabolism · 2019Trial
- Sotagliflozin in Combination With Optimized Insulin Therapy in Adults With Type 1 Diabetes: The North American inTandem1 Study.Diabetes care · 2018Trial
- Optimizing Hybrid Closed-Loop Therapy in Adolescents and Emerging Adults Using the MiniMed 670G System.Diabetes care · 2018Trial
- Continuous Glucose Monitoring in Older Adults With Type 1 and Type 2 Diabetes Using Multiple Daily Injections of Insulin: Results From the DIAMOND Trial.Journal of diabetes science and technology · 2017Trial
- REPLACE-BG: A Randomized Trial Comparing Continuous Glucose Monitoring With and Without Routine Blood Glucose Monitoring in Adults With Well-Controlled Type 1 Diabetes.Diabetes care · 2017Trial
- Hypoglycemia Reduction and Changes in Hemoglobin A1c in the ASPIRE In-Home Study.Diabetes technology & therapeutics · 2015Trial
- And the Dog Was Barking: Transforming Quality of Life in Diabetes Through Innovative Hypoglycemia Detection.Journal of diabetes · 2025Article
- Effect of switching from twice-daily basal insulin to once-daily insulin glargine 300 U/mL (Gla-300) in Brazilian people with type 1 diabetes.Diabetology & metabolic syndrome · 2024Article
- Utility and precision evidence of technology in the treatment of type 1 diabetes: a systematic review.Communications medicine · 2023Article
- Impact of continuous glucose monitoring on glycemic control and its derived metrics in type 1 diabetes: a longitudinal study.Frontiers in endocrinology · 2023Article
- Clinical Considerations for Insulin Therapy in Older Adults with Type 1 Diabetes.Drugs & aging · 2022Review
- Predicting changes in glycemic control among adults with prediabetes from activity patterns collected by wearable devices.NPJ digital medicine · 2021Article
- Couples Managing Type 1 Diabetes Using Diabetes Technology.Diabetes spectrum : a publication of the American Diabetes Association · 2021Article
- The Digital/Virtual Diabetes Clinic: The Future Is Now-Recommendations from an International Panel on Diabetes Digital Technologies Introduction.Diabetes technology & therapeutics · 2021Article
- Improved Real-World Glycemic Control With Continuous Glucose Monitoring System Predictive Alerts.Journal of diabetes science and technology · 2021Article
- Real world hybrid closed-loop discontinuation: Predictors and perceptions of youth discontinuing the 670G system in the first 6 months.Pediatric diabetes · 2020Observational
- Treatment Intensification With Insulin Pumps and Other Technologies in Patients With Type 2 Diabetes: Results of a Physician Survey in the United States.Clinical diabetes : a publication of the American Diabetes Association · 2020Article
Corrections and comments
- Commented on by
Authors and funding
8 authors at 6 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundASPIRE In-Home randomized 247 subjects with type 1 diabetes to sensor-augmented pump therapy with or without the Threshold Suspend (TS) feature, which interrupts insulin delivery at a preset sensor glucose value. We studied the effects of TS on nocturnal hypoglycemia (NH) in relation to baseline hemoglobin A1c (A1C) and change in A1C during the study. MATERIALS AND
methodsNH event rates and mean area under curve (AUC) of NH events were evaluated at different levels of baseline A1C (<7%, 7-8%, and >8%) and at different levels of changes in A1C (less than -0.3% [decreased], -0.3% to 0.3% [stable], and >0.3% [increased]), in the TS Group compared with the Control Group (sensor-augmented pump only).
resultsIn the TS Group, 27.9% of the NH events were accompanied by a confirmatory blood glucose value, compared with 39.3% in the Control Group. Among subjects with baseline A1C levels of <7% or 7-8%, those in the TS Group had significantly lower NH event rates than those in the Control Group (P=0.001 and P=0.004, respectively). Among subjects with decreased or stable A1C levels, those in the TS Group had significantly lower NH event rates, and the events had lower AUCs (P≤0.001 for each). Among subjects with increased A1C levels, those in the TS Group had NH events with significantly lower AUCs (P<0.001).
conclusionsUse of the TS feature was associated with decreases in the rate and severity (as measured by AUC) of NH events in many subjects, including those with low baseline A1C levels and those whose A1C values decreased during the study period. Use of the TS feature can help protect against hypoglycemia in those wishing to intensify diabetes management to achieve target glucose levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.